Doctors call Semaglutide a game changer in the prevention of Type 2 Diabetes among obese patients.
Mitchel L. Zoler, PhD
Treatment of people with obesity but without diabetes using the glucagon-like peptide-1 (GLP-1) agonist semaglutide (Wegovy) led to beneficial changes in body mass index (BMI), glycemic control, and other clinical measures.
This collectively cut the calculated risk for possible future development of type 2 diabetes in study participants by more than half, based on post-hoc analysis of data from two pivotal trials that compared semaglutide with placebo.
The findings “suggest that semaglutide could help prevent type 2 diabetes in people with overweight or obesity,” said W. Timothy Garvey, MD, in a presentation at the European Association for the Study of Diabetes 2022 Annual Meeting.
Enjoy more articles about this topic.
ClinicalPosters offers human anatomy charts, scientific posters, and other services that compliment articles about this topic. Slide extra posters into DeuPair Frames without removing from the wall.
Show your support by leaving an encouraging comment to keep the research going.
Support the writing of useful articles about this topic by exploring human anatomy charts, scientific posters, and other products online. You may sponsor specific articles.
ClinicalPosters provides human anatomy charts, scientific posters, and other products that compliment useful articles about this topic.
ClinicalPosters offers human anatomy charts, scientific posters, and other products online.
You can sponsor useful articles about this topic or donate to further research. Visible content is optimized for device size.
